Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Indian J Cancer ; 54(1): 178-181, 2017.
Article in English | MEDLINE | ID: mdl-29199685

ABSTRACT

The increasing cases of NSCLC and improved understanding of its molecular biology has lead to identification of its varied driver mutations. cMET amplification has an important role as resistance mechanism for EGFR TKIs. Crizotinib is a drug which shows its anti-tumoral effect in cMET positive cases. Here we present a case series of three such patients who achieved were cMET amplified and showed partial response on Crizotinib.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Proto-Oncogene Proteins c-met/genetics , Pyrazoles/administration & dosage , Pyridines/administration & dosage , Aged , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Crizotinib , Drug Resistance, Neoplasm/genetics , Female , Humans , Male , Middle Aged , Mutation , Protein Kinase Inhibitors/administration & dosage
2.
Indian J Cancer ; 54(1): 193-196, 2017.
Article in English | MEDLINE | ID: mdl-29199689

ABSTRACT

BACKGROUND: Recent advances and understanding in the field of lung cancer and advent of newer treatments have shown a significant improvement in survival in the patients. The present study was conducted to analyze the clinical profile of nonsmall cell lung cancer (NSCLC) patients treated in a single unit at a tertiary cancer care center. MATERIALS AND METHODS: In this retrospective analysis, 322 consecutive NSCLC patients from the year 2011 to 2012 treated in a single unit were included in the study. Patients with proven NSCLC were included in the study. The details of the patients included the demographic profile, pathological diagnosis as well as imaging data, tumor profile, details of treatment, and follow-up information. RESULTS: The majority of the patients (95.6%) were in the age group >40 years. A large group of the patients (57.1%) were present/reformed smokers. The major histological type was adenocarcinoma (60.9%), of which 22.8% patients were found to be epidermal growth factor receptor positive. Anaplastic lymphoma kinase rearrangement positivity rate was 4.8%. Furthermore, 68% patients had Stage 4 disease. Upfront palliative chemotherapy (CT) was offered in 61.8% patients and pemetrexed with platinum compounds was the main CT regimen (46.6%). Partial response was achieved in 45.7% patients, whereas stable disease was observed in 10.9% cases. Median progression-free survival was 5 months and overall survival was 55% at 36 months. CONCLUSION: NSCLC forms the largest subgroup of lung cancer with the patients presenting with advanced stages of disease. This area needs to be explored for the early detection and subsequently the radical treatment of the patients. Personalized approach may be considered for the management of lung cancer by identifying new predictive and prognostic biomarkers of this disease.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/epidemiology , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/epidemiology , Adenocarcinoma/pathology , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/pathology , Disease-Free Survival , ErbB Receptors/genetics , Female , Humans , Male , Middle Aged , Neoplasm Staging , Pemetrexed/administration & dosage , Pemetrexed/adverse effects , Platinum/administration & dosage , Platinum/adverse effects , Precision Medicine , Retrospective Studies , Tertiary Care Centers
3.
Indian J Cancer ; 54(Supplement): S37-S44, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29292707

ABSTRACT

Metastases to central nervous system (CNS) are very common in nonsmall cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-positive mutation. Brain is the most affected part of CNS where blood-brain barrier (BBB) presents a challenge to currently available chemotherapeutic agents as well as first- (erlotinib and gefitinib) and second (afatinib)-generation EGFR tyrosine kinase inhibitors (TKIs) due to their poor penetrability. A rapid development of EGFR T790M secondary mutation is another cause of treatment failure, and patients tend to progress despite initial response to first- and second-generation EGFR TKIs. Moreover, conventional treatments with heavy dose of radiation have a number of side effects compared to benefits attained. Recently, third-generation EGFR TKIs have been developed with proven efficacy in various clinical setups against EGFR mutation-positive cases of brain metastases in NSCLC. One such agent, osimertinib, is available in India. It has not only better penetration ability to BBB compared to other EGFR TKIs but also has significantly increased potency for most prevalent EGFR T790M mutations. Furthermore, it is active in patients who progress upon first- and second-generation EGFR TKIs. The purpose of this review article is to present an updated clinical preview of EGFR TKIs over conventional treatment, mainly radiation therapy to consider them as "use first" agents against EGFR T790M mutation in the treatment of patients with advanced NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Central Nervous System Neoplasms/drug therapy , ErbB Receptors/genetics , Protein Kinase Inhibitors/therapeutic use , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Central Nervous System Neoplasms/genetics , Central Nervous System Neoplasms/pathology , Central Nervous System Neoplasms/secondary , Humans , Mutation , Neoplasm Staging
4.
South Asian J Cancer ; 5(4): 167-175, 2016.
Article in English | MEDLINE | ID: mdl-28032079

ABSTRACT

The Oncology Gold Standard (OGS) Expert Group on renal cell carcinoma (RCC) developed the consensus statement to provide community oncologists practical guidelines on the management of advanced clear cell (cc) RCC using published evidence, practical experience of experts in real life management, and results of a nationwide survey involving 144 health-care professionals. Six broad question categories containing 33 unique questions cover major situations in the routine management of RCC. This document serves as a ready guide for the standard of care to optimize outcome. The table of "Take Home Messages" at the end is a convenient tool for busy practitioners.

5.
Indian J Cancer ; 53(3): 448-451, 2016.
Article in English | MEDLINE | ID: mdl-28244481

ABSTRACT

OBJECTIVES: To examine the epidemiology of microbiologically documented bacterial infection and the resistance pattern, among cancer patients undergoing treatment at RGCIRC, Delhi. DESIGN AND SETTING: Retrospective observational study in which culture reports obtained over 1 year in 2013, were analyzed. RESULTS: 13329 cultures were obtained over 1 year in 2013 and were analyzed. 23.6 % samples showed positive culture with majority being gram negative isolates (67.9 %). E. coli was the commonest gram negative isolate (49.4%) followed by klebsella (29.7%) and Staph. aureus was the commonest gram positive isolate. There was high incidence of ESBL in blood and urine (87.2% & 88.5%) and BLBLI were also high (78% & 83.9%). Carbapenem resistance was comparatively low (10%) and colistin sensitivity was quiet high (> 95%). CONCLUSIONS: Prevalence of MRSA and VRE in our institute is very less, whereas prevalence of ESBLs and BLBLI isolates amongst gram negative infections is around 80%. Gram negative isolates had poor sensitivity to cephalosporins and fluoroquinolones.


Subject(s)
Bacterial Infections/epidemiology , Bacterial Infections/microbiology , Neoplasms/epidemiology , Neoplasms/microbiology , Tertiary Healthcare/statistics & numerical data , Bacterial Infections/blood , Bacterial Infections/urine , Drug Resistance, Bacterial , Humans , India/epidemiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Neoplasms/blood , Neoplasms/urine , Prevalence , Retrospective Studies , Vancomycin-Resistant Enterococci/drug effects , Vancomycin-Resistant Enterococci/isolation & purification
7.
Aust Vet J ; 63(8): 251-3, 1986 Aug.
Article in English | MEDLINE | ID: mdl-3790011

ABSTRACT

The mean percentage of cells forming rosettes with 2-aminoethyl isothiouronium bromide-treated sheep erythrocytes (EAETRFC) in the peripheral blood of 10 horn cancer-affected cattle (40.05 +/- 2.91) was significantly low in comparison to the value in unaffected control animals (58.61 +/- 1.68). Immunotherapy with a saline phenol extract of allogeneic tumour tissue resulted in a gradual increase in the mean percentage of EAETRFC on each subsequent week. The increase was statistically significant from the second week onwards and on the sixth week, the percentage of EAETRFC in horn cancer affected cattle (56.80 +/- 1.38) closely approximated the value in unaffected controls.


Subject(s)
Carcinoma, Squamous Cell/veterinary , Cattle Diseases/immunology , Horns , Neoplasms/veterinary , Analysis of Variance , Animals , Carcinoma, Squamous Cell/immunology , Carcinoma, Squamous Cell/therapy , Cattle , Cattle Diseases/therapy , Female , Immunity, Cellular , Immunotherapy , Male , Neoplasms/immunology , Neoplasms/therapy , Phenol , Phenols , Rosette Formation
SELECTION OF CITATIONS
SEARCH DETAIL
...